Katherine Yang1, B Joseph Guglielmo. 1. Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, San Francisco, CA 94143, USA. yangk@pharmacy.ucsf.edu
Abstract
OBJECTIVE: To review the laboratory diagnosis of extended-spectrum beta-lactamase (ESBL) and AmpC beta-lactamase-producing bacteria and evaluate potential treatment options. DATA SOURCES: A PubMed search, restricted to English-language articles, was conducted (1966-May 2007) using the search terms ESBL, AmpC, diagnosis, detection, carbapenem, ertapenem, fluoroquinolone, cephalosporin, cefepime, tigecycline, and colistin. Additional references were identified through review of bibliographies of identified articles. STUDY SELECTION AND DATA EXTRACTION: All studies that evaluated laboratory methods for the detection of ESBLs and AmpC beta-lactamases and/or the treatment of these organisms were reviewed. All articles that were deemed to be clinically pertinent were included and critically evaluated. DATA SYNTHESIS: Numerous laboratory techniques are available for the detection of ESBLs. In contrast, laboratory techniques for detection of AmpC beta-lactamases are limited, particularly for plasmid-mediated AmpC beta-lactamases. Routine microbiologic testing may not detect ESBLs or AmpC beta-lactamases. Optimal antibiotic treatment options are derived from limited observational studies and case reports. Randomized clinical trials evaluating appropriate antibiotic treatment options are lacking. In vitro susceptibility does not always correlate with clinical outcomes. The use of imipenem was associated with the lowest incidence of mortality in patients with bacteremia due to ESBL-producing organisms. CONCLUSIONS: Laboratory detection of ESBLs for most organisms is possible with Clinical and Laboratory Standards Institute-recommended testing. However, these tests can be associated with both false negative and false positive results, particularly with organisms that harbor both ESBL- and plasmid-mediated AmpC beta-lactamases. No established guidelines exist for the detection of AmpC beta-lactamases. Imipenem and meropenem are superior to other antibiotics for the treatment of serious infections due to ESBL and AmpC beta-lactamase-producing gram-negative bacteria. While in vitro data demonstrate that tigecycline, ertapenem, and colistin might be potential choices, clinical experience is lacking.
OBJECTIVE: To review the laboratory diagnosis of extended-spectrum beta-lactamase (ESBL) and AmpC beta-lactamase-producing bacteria and evaluate potential treatment options. DATA SOURCES: A PubMed search, restricted to English-language articles, was conducted (1966-May 2007) using the search terms ESBL, AmpC, diagnosis, detection, carbapenem, ertapenem, fluoroquinolone, cephalosporin, cefepime, tigecycline, and colistin. Additional references were identified through review of bibliographies of identified articles. STUDY SELECTION AND DATA EXTRACTION: All studies that evaluated laboratory methods for the detection of ESBLs and AmpC beta-lactamases and/or the treatment of these organisms were reviewed. All articles that were deemed to be clinically pertinent were included and critically evaluated. DATA SYNTHESIS: Numerous laboratory techniques are available for the detection of ESBLs. In contrast, laboratory techniques for detection of AmpC beta-lactamases are limited, particularly for plasmid-mediated AmpC beta-lactamases. Routine microbiologic testing may not detect ESBLs or AmpC beta-lactamases. Optimal antibiotic treatment options are derived from limited observational studies and case reports. Randomized clinical trials evaluating appropriate antibiotic treatment options are lacking. In vitro susceptibility does not always correlate with clinical outcomes. The use of imipenem was associated with the lowest incidence of mortality in patients with bacteremia due to ESBL-producing organisms. CONCLUSIONS: Laboratory detection of ESBLs for most organisms is possible with Clinical and Laboratory Standards Institute-recommended testing. However, these tests can be associated with both false negative and false positive results, particularly with organisms that harbor both ESBL- and plasmid-mediated AmpC beta-lactamases. No established guidelines exist for the detection of AmpC beta-lactamases. Imipenem and meropenem are superior to other antibiotics for the treatment of serious infections due to ESBL and AmpC beta-lactamase-producing gram-negative bacteria. While in vitro data demonstrate that tigecycline, ertapenem, and colistin might be potential choices, clinical experience is lacking.
Authors: Emilio Bouza; Ana Pérez; Patricia Muñoz; M Jesús Pérez; Cristina Rincón; Carlos Sánchez; Pablo Martín-Rabadán; Mariano Riesgo Journal: Crit Care Med Date: 2003-07 Impact factor: 7.598
Authors: Jordi Rello; Carmen Lorente; Emili Diaz; Maria Bodi; Carmen Boque; Albert Sandiumenge; Josep Maria Santamaria Journal: Chest Date: 2003-12 Impact factor: 9.410
Authors: P Depuydt; D Benoit; D Vogelaers; J Decruyenaere; D Vandijck; G Claeys; G Verschraegen; S Blot Journal: Intensive Care Med Date: 2007-12-08 Impact factor: 17.440
Authors: Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Tarek S Mansour; Steven J Projan; Patricia A Bradford Journal: Antimicrob Agents Chemother Date: 2008-11-10 Impact factor: 5.191
Authors: Tat Ming Ng; Wendy X Khong; Patrick N A Harris; Partha P De; Angela Chow; Paul A Tambyah; David C Lye Journal: PLoS One Date: 2016-04-22 Impact factor: 3.240